Palvella Therapeutics (PVLA) FCF Margin (2014 - 2024)
Palvella Therapeutics (PVLA) posted quarterly FCF Margin of 2079.25% for Q1 2024, down 152979.0% year-over-year from N/an in Q2 2023, and down 184.55% quarter-over-quarter from 730.71% in Q4 2023.
Powered by 
Analysis
Palvella Therapeutics (PVLA) FCF Margin (2014 - 2024) Analysis & Trends
Palvella Therapeutics (PVLA) has reported FCF Margin for 11 consecutive years, with 2079.25% the latest figure, recorded in Q1 2024.
- In Q1 2024, FCF Margin fell 152979.0% year-over-year to 2079.25%; the TTM figure through Sep 2024 stood at 546.52% (down 43081.0% YoY), while the FY2023 annual figure was 35.84%, up 1404568.0% from the prior year.
- FCF Margin eased to 2079.25% in Q1 2024 per PVLA's latest filing, from 730.71% in the prior quarter.
- Across five years, FCF Margin topped out at 3983.49% in Q2 2021 and bottomed at 10177.37% in Q4 2022.
- Historically, FCF Margin has averaged 1213.68% across 5 years, with a median of 209.61% in 2022.
- Annual changes were most pronounced in 2022 — FCF Margin plunged 1103001 bps — and 2023, when it soared 944666 bps.
- Palvella Therapeutics' FCF Margin stood at 395.9% in 2020, then sank by 134 bps to 133.67% in 2021, then tumbled by 7514 bps to 10177.37% in 2022, then soared by 93 bps to 730.71% in 2023, then sank by 185 bps to 2079.25% in 2024.
- Business Quant data shows PVLA's FCF Margin at 2079.25% in Q1 2024, 730.71% in Q4 2023, and 50.16% in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Palvella Therapeutics | 2.24 Bn | 1.93 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2024 | -2,079.25% |
| Dec 31, 2023 | 1,575.06% |
| Sep 30, 2023 | -50.16% |
| Jun 30, 2023 | -67.20% |
| Mar 31, 2023 | -549.45% |
| Dec 31, 2022 | -221.04% |
| Sep 30, 2022 | -164.10% |
| Jun 30, 2022 | -438.26% |
| Mar 31, 2022 | -206.01% |
| Dec 31, 2021 | -133.67% |
| Sep 30, 2021 | -365.64% |
| Jun 30, 2021 | 903.41% |
| Mar 31, 2021 | -93.58% |
| Dec 31, 2020 | -745.60% |
| Sep 30, 2020 | -228.99% |
| Jun 30, 2020 | -96.38% |
| Mar 31, 2020 | -128.63% |
| Dec 31, 2019 | -87.72% |
| Sep 30, 2019 | -85.14% |
| Jun 30, 2019 | -218.79% |